信立泰(002294) - 2024 Q1 - 季度财报

Financial Performance - The company reported a revenue of CNY 1,090,969,117.78 for Q1 2024, representing a year-on-year increase of 22.92% compared to CNY 887,511,571.76 in the same period last year[4]. - Net profit attributable to shareholders was CNY 200,265,316.30, a decrease of 5.06% from CNY 210,947,894.80 in the previous year[4]. - The net profit after deducting non-recurring gains and losses was CNY 201,466,979.90, reflecting a growth of 4.50% from CNY 190,290,710.43 year-on-year[4]. - Basic and diluted earnings per share were both CNY 0.180, down 5.26% from CNY 0.190 in the same period last year[5]. - The net profit for Q1 2024 was CNY 198,111,870.96, a decrease of 5.7% compared to CNY 208,695,134.62 in Q1 2023[25]. - The total profit before tax was CNY 230,734,563.27, down from CNY 242,035,575.13 in Q1 2023, reflecting a decrease of 4.9%[25]. - The company reported a total comprehensive income of CNY 198,712,294.65 for Q1 2024, slightly down from CNY 200,895,309.35 in Q1 2023[26]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 83.54% to CNY 230,125,911.32, up from CNY 125,382,415.26 in the previous year[4]. - Cash and cash equivalents at the end of Q1 2024 amounted to CNY 1,408,526,834.29, an increase from CNY 2,309,274,747.23 at the end of Q1 2023[28]. - Cash and cash equivalents decreased to CNY 10,000,000.00 from CNY 40,000,000.00 in the previous quarter, indicating a liquidity contraction[22]. - The cash flow from investing activities showed a net outflow of CNY 106,552,137.82, an improvement from a net outflow of CNY 237,575,476.00 in Q1 2023[28]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,610,056,240.51, an increase of 2.27% from CNY 9,396,672,754.02 at the end of the previous year[5]. - The company's total assets as of Q1 2024 amounted to CNY 9,610,056,240.51, up from CNY 9,396,672,754.02 at the end of the previous quarter[23]. - The total liabilities for Q1 2024 were CNY 1,347,801,552.73, compared to CNY 1,341,246,394.27 in the previous quarter[22]. - Non-current assets totaled CNY 6,111,768,678.14, slightly increasing from CNY 6,083,450,830.35[22]. Shareholder Information - Shareholders' equity attributable to the parent company was CNY 8,226,388,265.77, up 2.59% from CNY 8,018,993,837.21 at the end of the previous year[5]. - The company has a total of 635,279,380 shares held by its largest shareholder, accounting for 55.56% of total shares[12]. - The second-largest shareholder holds 52,300,800 shares, representing 4.49% of total shares[12]. - The company’s total shares held by the top 10 shareholders account for 23.45% of total shares[12]. Research and Development - The company increased its investment in product promotion and innovative R&D, leading to a 37.31% rise in selling expenses and a 38.95% increase in R&D expenses compared to the previous year[8]. - Research and development expenses increased to CNY 107,577,291.57, compared to CNY 77,421,412.52 in Q1 2023, marking a 39% rise[24]. - The company plans to accelerate the promotion of its innovative drugs, particularly after the inclusion of Enalapril in the medical insurance directory[8]. - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[24]. Financial Management - The company raised a total of RMB 195,187.12 million from the issuance of 68,800,535 shares at a price of RMB 28.37 per share, with a net amount of RMB 193,206.57 million after deducting issuance costs[14]. - As of March 31, 2024, the company has invested RMB 103,027.66 million of the raised funds, with RMB 2,009.85 million invested in the current year[15]. - The company reported a balance of RMB 99,919.12 million in its fundraising account as of March 31, 2024, with interest income of RMB 229.95 million for the year[15]. - The company has engaged in wealth management with a total amount of RMB 104,538.00 million, with no overdue amounts reported[17]. - The company has not engaged in any high-risk wealth management products during the reporting period[18]. - The company has not reported any overdue commitments or non-operating fund occupation by controlling shareholders during the reporting period[16]. Inventory and Receivables - The company’s receivables increased by 130.11% to CNY 101,465,300.00, primarily due to a rise in revenue and increased bill settlements[8]. - The accounts receivable stood at 470,274,134.53, slightly up from 467,398,830.97, indicating a stable collection performance[21]. - The total inventory reported was 457,276,766.61, down from 490,857,450.66, suggesting improved inventory management[21].